Zar Niklas, Garmo Hans, Holmberg Lars, Rastad Jonas, Hellman Per
Department of Surgery, Ryhov County Hospital, SE-551 85 Jönköping, Sweden.
World J Surg. 2004 Nov;28(11):1163-8. doi: 10.1007/s00268-004-7610-2.
Midgut carcinoid tumors are rare and have a markedly better prognosis than adenocarcinoma in the small intestine. New diagnostic methods and medical as well as surgical therapies have evolved during the last decades, leading to more active care of these patients. Patients with small intestinal carcinoids diagnosed from 1960 to 2000 in the duodenum (n = 89) and jejunum/ileum (n = 2437) were identified in the Swedish Cancer Registry. Cases without histologic verification and autopsy cases were excluded. Overall, cause-specific and relative survival were calculated. The overall 5-, 10-, and 15 year survivals were, respectively, 60%, 46%, and 28% for duodenal tumors and 56%, 36%, and 23% for jejunal/ileal tumors. Cause-specific 5-, 10-, and 15-year survival was 94% for all three follow-up periods for duodenal tumors and 87%, 80%, and 77% for those in the jejunum/ileum. The corresponding relative survivals were, respectively, 72%, 67%, and 51% for duodenal tumors and 67%, 54%, and 44% for those in the jejunum/ileum. Sex did not influence overall or cause-specific survival. The age at diagnosis correlated inversely with overall and cause-specific survival for tumors in the jejunum/ileum. For tumors in the jejunum/ileum, the overall and cause-specific survival correlated with the time period of diagnosis, with a more favorable prognosis for those diagnosed in recent years. A multivariate Cox proportional hazards model showed similar results. We concluded that young age and diagnosis in recent years are positive predictors of survival for patients with midgut carcinoids. The divergence between cause-specific and relative survival implies the need for a more detailed analysis of the causes of death of these patients.
中肠类癌肿瘤较为罕见,其预后明显优于小肠腺癌。在过去几十年中,新的诊断方法以及药物和手术治疗方法不断发展,使得对这些患者的治疗更加积极。在瑞典癌症登记处识别出了1960年至2000年期间在十二指肠(n = 89)和空肠/回肠(n = 2437)中诊断出的小肠类癌患者。排除了未经组织学验证的病例和尸检病例。总体上,计算了特定病因生存率和相对生存率。十二指肠肿瘤的总体5年、10年和15年生存率分别为60%、46%和28%,空肠/回肠肿瘤的相应生存率分别为56%、36%和23%。十二指肠肿瘤在所有三个随访期的特定病因5年、10年和15年生存率均为94%,空肠/回肠肿瘤的相应生存率分别为87%、80%和77%。十二指肠肿瘤的相应相对生存率分别为72%、67%和